COVID-19 cases in the Americas increased 10.4 percent last week from the previous one, but countries must also pay attention to a rise in other respiratory viruses in the region, the Pan American Health Organization (PAHO) said on Wednesday.
Use of Pfizer Inc.’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.
The World Health Organization’s governing board agreed on Monday to form a new committee to help speed up its response to health emergencies like COVID-19.
Countries have agreed to an initial U.S.-led push to reform the rules around disease outbreaks, known as the International Health Regulations, after early opposition from Africa and others was overcome this week, sources told Reuters on Friday.
As cases and news of monkeypox spread globally, scientists are investigating the unprecedented outbreak. BioSpace compiled updates about tracking, origins and treatments concerning monkeypox.
Patients who experience recurrence of COVID-19 symptoms after completing treatment with Pfizer’s drug Paxlovid should isolate again for five days, the U.S. Centers for Disease Control and Prevention said in an advisory issued on Tuesday.
North Korea on May 21 reported more than 200,000 new patients suffering from fever for a fifth consecutive day, as the country fought its first confirmed coronavirus outbreak.
Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86 percent of genomics studies to date have involved people of European ancestry, which has limited the potential benefits of genomic research for many populations. Rebecca Sutphen, Co-Founder and Chief Medical Officer of InformedDNA, and Board-Certified Genetic Counselor Karmen Trzupek analyze strategies to increase diversity in rare genetic disease trials.
Pharmacovigilance, the industry term for drug safety, was unfamiliar to most of the general public before March 2020. But as the coronavirus pandemic unfolded, its rapid spread thrust drug safety into the spotlight. The public is more aware of drug safety and health regulators’ role than ever — and as the demand for pharmacovigilance information rises, the industry has had to find ways to keep up — according to Beena Wood, VP of safety at ArisGlobal.
If you flip through history, you’ll realize that our fundamental healthcare needs haven’t changed since the year 1885. We still seek rest when we’re ill, feel pain when we overexert ourselves, and need guidance from experts on our health and wellness. But the tools we have to meet these perennial needs have shifted dramatically since the 19th century, and especially over the past decade, wherein technology has advanced faster than even the greatest Sci-Fi film producers imagined, according to Greater Than One Chief Technology Officer Ken Winell.